JONATHAN LEI to Proteogenomics
This is a "connection" page, showing publications JONATHAN LEI has written about Proteogenomics.
Connection Strength
2.879
-
Proteogenomics drives therapeutic hypothesis generation for precision oncology. Br J Cancer. 2021 07; 125(1):1-3.
Score: 0.645
-
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Rep Med. 2025 Aug 19; 6(8):102255.
Score: 0.218
-
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Cell Rep Med. 2025 Jun 17; 6(6):102154.
Score: 0.216
-
Mapping the functional network of human cancer through machine learning and pan-cancer proteogenomics. Nat Cancer. 2025 Jan; 6(1):205-222.
Score: 0.208
-
Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell. 2024 Aug 08; 187(16):4389-4407.e15.
Score: 0.202
-
A proteogenomics data-driven knowledge base of human cancer. Cell Syst. 2023 09 20; 14(9):777-787.e5.
Score: 0.190
-
Proteogenomic data and resources for pan-cancer analysis. Cancer Cell. 2023 08 14; 41(8):1397-1406.
Score: 0.190
-
Proteogenomic insights suggest druggable pathways in endometrial carcinoma. Cancer Cell. 2023 09 11; 41(9):1586-1605.e15.
Score: 0.190
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
Score: 0.189
-
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
Score: 0.180
-
A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021 08 05; 184(16):4348-4371.e40.
Score: 0.165
-
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020 11 25; 183(5):1436-1456.e31.
Score: 0.157
-
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. Cancer Cell. 2025 Sep 08; 43(9):1731-1757.e17.
Score: 0.054
-
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021 03 08; 39(3):361-379.e16.
Score: 0.040
-
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A. 2018 12 18; 115(51):E11978-E11987.
Score: 0.034